Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.1% After Analyst Upgrade

Nurix Therapeutics, Inc. (NASDAQ:NRIX)’s stock price was up 4.1% during trading on Wednesday after Oppenheimer raised their price target on the stock from $28.00 to $32.00. Oppenheimer currently has an outperform rating on the stock. Nurix Therapeutics traded as high as $22.71 and last traded at $23.0280. Approximately 216,821 shares traded hands during trading, a decline of 85% from the average daily volume of 1,484,036 shares. The stock had previously closed at $22.13.

Several other equities research analysts have also commented on the stock. Mizuho upped their price target on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday. HC Wainwright raised their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday, July 10th. Finally, Stifel Nicolaus set a $41.00 price target on shares of Nurix Therapeutics in a report on Tuesday. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Insiders Place Their Bets

In related news, CFO Hans van Houte sold 4,761 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 1,452 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total transaction of $36,982.44. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,985,771.69. The trade was a 1.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,372 shares of company stock worth $518,463 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the registrational Phase 3 DAYBreak CLL-306 trial, testing bexobrutideg against pirtobrutinib (JAYPIRCA) in relapsed/refractory CLL/SLL. The trial could support an accelerated approval filing and potentially establish a stronger competitive position for the drug. Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Nurix reported third-quarter earnings of $4.73 per share versus the consensus estimate of a $0.56 loss, while revenue of $673.1 million substantially exceeded the approximately $24.4 million forecast. The earnings beat provides near-term financial support, though investors may examine how recurring and sustainable the results are. Nurix Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Analysts remain constructive: Baird raised its price target to $36 with an “outperform” rating, Needham reaffirmed “buy” with a $34 target, and Truist maintained “buy” despite trimming its target to $33. Nurix Therapeutics Q3 2026 Earnings
• Positive Sentiment: A Seeking Alpha analysis maintained a “Strong Buy,” citing bexobrutideg’s pivotal progress, partnership potential and Nurix’s financial resources. Nurix Maintaining Strong Buy
• Neutral Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, reinforcing the possibility of valuation upside if clinical and commercial milestones are delivered. Nurix Enterprise Value Remains Underappreciated
• Negative Sentiment: Analysts flagged risks tied to Nurix’s reliance on Roche, including cost burdens, reduced control over development or commercialization and uncertain returns from bexobrutideg. These concerns could limit enthusiasm despite the favorable clinical updates. Nurix’s Reliance on Roche and Bexobrutideg Risks

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds have recently made changes to their positions in NRIX. BlackRock Inc. purchased a new position in Nurix Therapeutics during the 2nd quarter worth approximately $212,769,000. General Atlantic L.P. purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $92,899,000. Baker BROS. Advisors LP boosted its holdings in Nurix Therapeutics by 20.0% during the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after buying an additional 776,431 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Nurix Therapeutics by 151.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock valued at $67,455,000 after buying an additional 2,139,728 shares in the last quarter. Finally, Trails Edge Capital Partners LP purchased a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $38,166,318.

Nurix Therapeutics Stock Up 4.9%

The firm has a market cap of $2.41 billion, a price-to-earnings ratio of -6.74 and a beta of 1.82. The business has a 50 day moving average of $25.17 and a 200 day moving average of $21.00.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a return on equity of 62.20% and a net margin of 42.01%. Research analysts predict that Nurix Therapeutics, Inc. will post -2.69 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.